PlainPill

Ibogaine

The short answer. There isn't much data on Ibogaine yet — 17 mentions, 5 with a clear outcome — so treat these numbers as anecdotal. There is a moderate body of research — 13 meta-analyses and 3 trials.

What users report
80%helped5 reports · few reports
4 helped1 mixed0 didn't help

From 17 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
BModerate research base
13
meta-analyses
3
RCTs
530
papers

What Ibogaine does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

BModerate research base

At least one meta-analysis, or 5+ randomized controlled trials. The grade measures how much human research exists — read the conclusions below for what it found. 13 meta-analyses on PubMed ↗ · 3 randomized trials ↗

Transl Psychiatry · 2016 · Meta-analysis / systematic review
Ibogaine and addiction in the animal model, a systematic review and meta-analysis

Conclusion: Our results warrant further studies into the clinical efficacy of ibogaine in SUD patients in reducing craving and substance use, but close monitoring of the patients is recommended because of the possible toxic effects. In addition, more work is needed to unravel the neuropharmacological working mechanisms of ibogaine and to investigate its effects on heart rhythm.

PubMed 27244235 ↗
J Subst Abuse Treat · 2022 · Meta-analysis / systematic review
A systematic literature review of clinical trials and therapeutic applications of ibogaine

Conclusion: Treatment of SUDs and persisting comorbidities requires innovative treatment approaches. Rapid-onset therapies such as the application of ibogaine may offer novel treatment opportunities for specific individuals. Rigorous study designs within medical settings are necessary to warrant safe application, monitoring, and, possibly, medical intervention.

PubMed 35012793 ↗
Drug Alcohol Depend · 2023 · Meta-analysis / systematic review
Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials

Conclusion: Bupropion showed a significant modest reduction in ATS use and ATS craving (both rated as very low-quality evidence), larger in males (craving), and with longer treatment (ATS use). These results may inform future studies. More research is warranted on who might benefit from bupropion as ATSUD treatment.

PubMed 37979478 ↗
Registered clinical trials

9 human trials on ClinicalTrials.gov test Ibogaine — 3 completed, 1 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

US legal status (DEA)

Ibogaine is a Schedule I controlled substance in the US. DEA controlled-substance list ↗

US government research funding (NIH)

NIH has funded 10 research projects with Ibogaine in the title, $10,202,007 in total (1994–2026). NIH RePORTER ↗

Dosage people report

As stated by users — not a recommendation. Follow the label or your doctor.

No doses stated in the reports so far.

Reported side effects

How often each side effect came up across all reports.

medical complications ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

Ibogaine compared

Other options for memory

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate